ESC Premium Access

Cardiovascular outcomes of new anti-diabetic agents - A meta-analysis of randomized controlled trials

Congress Presentation

About the speaker

Doctor Claudio Parco

University Hospital Duesseldorf, Duesseldorf (Germany)
0 follower

6 more presentations in this session

Circulating microparticules of patients with coronary artery disease up-regulate the expression of sodium-glucose cotransporters 1 and 2 in coronary artery endothelial cells: role of angiotensin II

Speaker: Doctor S. Park (Illkirch, FR)


Novel direct effects of SGLT2 inhibitor, Canagliflozin, on myocardial redox state in humans.

Speaker: Doctor H. Kondo (Yufu City, JP)


Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes

Speaker: Mr J. Ghouse (Copenhagen, DK)


Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

Speaker: Professor D. McGuire (Dallas, US)


The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis

Speaker: Professor C. Desouza (Omaha, US)


Access the full session

Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

Speakers: Doctor C. Parco, Doctor S. Park, Doctor H. Kondo, Mr J. Ghouse, Professor D. McGuire...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb